FDA May Delay Overhaul of Part 11, Agency Official Says

Washington Drug Letter
KEYWORDS FDA / Part 11
A A

The FDA is unlikely to complete its long-awaited revision of 21 CFR Part 11 — which regulates the use of electronic records and signatures — by the end of the year as industry observers had expected, an agency official said this month.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00